Plaque psoriasis has significant impact on patients’ quality of life. Topical therapy is considered the treatment mainstay for mild‐to‐moderate disease according to guidelines. Aims: To evaluate the clinical safety and efficacy and the patient’s quality of life with topical apremilast gel versus topical calcipotriol in mild to moderate plaque psoriasis. Materials and methods: This study was a single centre, prospective, parallel group, open label study. Patients were randomly allocated to any one of two groups . Patients in calcipotriol group (group C) were administered 0.005% calcipotriol for local application twice daily for 12 weeks Apremilast (group-A) were administered Apremilast Topical Gel, 2% w/w twice daily for local application on all lesions for 12 weeks. Results: After baseline matching, patients treated for 12 weeks with topical apremilast had greater response compared to those treated with topical Calcipotriol (P < 0.001). Patients treated with topical apremilast had significantly greater improvement Psoriasis Area and Severity Index (PASI) (P < 0.001). Conclusion: Despite recent treatment advances, unmet needs for psoriasis patients remain. Topical Apremilast offers improved efficacy in baseline matched psoriasis patients compared to topical Calcipotriol